Alliance Pharmaceutical responds to FDA
The San Diego developer of the ultrasound contrast medium Imavist has provided documentation requested by the FDA to support the companyπs application to market the agent in the U.S. The FDA had reviewed a new drug application for Imavist and found
The San Diego developer of the ultrasound contrast medium Imavist has provided documentation requested by the FDA to support the companyπs application to market the agent in the U.S. The FDA had reviewed a new drug application for Imavist and found it to be approvable upon satisfactory response to issues identified in the review process. Alliance and Schering of Germany are developing Imavist jointly. Alliance believes the current submission fully addresses the issues noted by the FDA, and the company hopes to receive final approval later this year.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.
